← Back to Clinical Trials
Recruiting NCT07337577

NCT07337577 Targeted Artificial Intelligence Language mOdel Recommendations for Heart Failure (TAILOR-HF)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07337577
Status Recruiting
Phase —
Sponsor Brigham and Women's Hospital
Condition Heart Failure
Study Type INTERVENTIONAL
Enrollment 500 participants
Start Date 2026-08-27
Primary Completion 2027-09-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
LLM-GDMT Clinical Decision Support Tool

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 500 participants in total. It began in 2026-08-27 with a primary completion date of 2027-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is an investigator-initiated, cluster-randomized implementation trial evaluating a large language model (LLM)-based clinical decision support (CDS) tool designed to improve guideline-directed medical therapy (GDMT) for adult patients with heart failure seen in outpatient cardiology clinics at Mass General Brigham. For eligible heart failure encounters, the CDS tool reviews existing electronic health record (EHR) data, including diagnoses, medications, vital signs, laboratory results, and recent notes, and generates brief, clinician-facing messages suggesting opportunities to initiate or optimize GDMT and highlighting relevant safety considerations. Messages are delivered to cardiology providers via Epic InBasket and/or institutional email prior to scheduled visits. The tool is advisory only and cannot place orders or change medications automatically; all treatment decisions remain at the discretion of the treating clinician and patient. Cardiology providers are assigned at the provider/clinic level to early implementation of the CDS tool versus usual care (no messages) during the initial phase. The primary outcome is GDMT optimization within 30 days of an index visit. Secondary outcomes include feasibility of CDS generation and delivery and a 30-day safety composite (e.g., heart failure hospitalization, acute kidney injury, hyperkalemia, hypotension or bradyarrhythmia plausibly related to GDMT).

Eligibility Criteria

Inclusion Criteria: * Age ≥18 years * Scheduled outpatient visit with a participating cardiology provider in an MGB outpatient cardiology clinic * At least one prior cardiology clinic visit in the MGB system within the past 2 years * Diagnosis of heart failure by ICD code within the past 2 years * Heart failure diagnosis supported by at least one of the following: * Current or recent use of a loop diuretic * Left ventricular ejection fraction ≤40% on the most recent echocardiogram * Explicit documentation of heart failure diagnosis or heart failure signs/symptoms in a prior cardiology note Exclusion Criteria: * Systolic blood pressure \<90 mmHg on the most recent recorded measurement * Heart rate \<50 beats per minute on the most recent recorded measurement * eGFR \<20 mL/min/1.73 m² on the most recent laboratory assessment * Known cardiac amyloidosis or hypertrophic cardiomyopathy * History of heart transplant or presence of a left ventricular assist device * Severe aortic stenosis, severe aortic insufficiency, or severe mitral stenosis on the most recent echocardiogram * Encounter occurs in an adult congenital heart disease clinic

Contact & Investigator

Central Contact

Jonathan W Cunningham, MD, MPH

✉ jcunningham3@bwh.harvard.edu

📞 617-732-8534

Frequently Asked Questions

Who can join the NCT07337577 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07337577 currently recruiting?

Yes, NCT07337577 is actively recruiting participants. Contact the research team at jcunningham3@bwh.harvard.edu for enrollment information.

Where is the NCT07337577 trial being conducted?

This trial is being conducted at Boston, United States.

Who is sponsoring the NCT07337577 clinical trial?

NCT07337577 is sponsored by Brigham and Women's Hospital. The trial plans to enroll 500 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology